Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/25/2025 | $52.00 | Buy | Jefferies |
| 3/7/2025 | $55.00 | Sector Outperform | Scotiabank |
| 3/3/2025 | $29.00 → $36.10 | Buy → Neutral | BofA Securities |
| 12/14/2023 | $47.50 | Overweight | Morgan Stanley |
| 8/10/2023 | $70.00 | Overweight | Cantor Fitzgerald |
| 3/2/2022 | $194.00 → $102.00 | Outperform | SVB Leerink |
| 1/21/2022 | $64.00 | Outperform | Macquarie |
| 12/15/2021 | $189.00 → $136.00 | Overweight | JP Morgan |
4 - Zai Lab Ltd (0001704292) (Issuer)
4 - Zai Lab Ltd (0001704292) (Issuer)
4 - Zai Lab Ltd (0001704292) (Issuer)
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced the Hong Kong Department of Health has approved TIVDAK (tisotumab vedotin-tftv) in Hong Kong for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. "Today's approval of TIVDAK marks an important milestone for Zai Lab, further strengthening our Women's franchise in Greater China," said Andrew Zhu, Chief Commercial Officer, Greater China, Zai Lab. "Treatment options for patients with recurrent or metastatic cervical cancer after initial therapy are limited. TIVDAK, the first antibody-drug conjugate (ADC) therapy in cervical cancer, delivers a clinically mea
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that members of the Company's senior management team will participate in the following investor conferences in September 2025: Cantor Global Healthcare Conference Presentation: Thursday, September 4, 2025, 10:20 a.m. ET Location: New York, NY Morgan Stanley 23rd Annual Global Healthcare Conference Fireside Chat: Tuesday, September 9, 2025, 2:35 p.m. ET Location: New York, NY Live webcasts will be available on the Investor Relations page of Zai Lab's website at ir.zailaboratory.com/webcasts-presentations and archived replays will be available for up to 90 days following the completion of the events. About Zai Lab Zai Lab (N
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that the China National Medical Products Administration (NMPA) has granted Innovative Medical Device Designation for Tumor Treating Fields (TTFields) for patients with pancreatic cancer based on the positive results from the Phase 3 PANOVA-3 trial. The Innovative Medical Device Designation allows Zai Lab to take advantage of an expedited approval procedure for TTFields that offers opportunities for the NMPA to prioritize the allocation of review resources to expedite the regulatory review and approval process. "We are excited that TTFields has been granted the Innovative Medical Device Designation, a status that offers expedited r
4 - Zai Lab Ltd (0001704292) (Issuer)
4 - Zai Lab Ltd (0001704292) (Issuer)
4 - Zai Lab Ltd (0001704292) (Issuer)
SCHEDULE 13G - Zai Lab Ltd (0001704292) (Subject)
144 - Zai Lab Ltd (0001704292) (Subject)
SCHEDULE 13G/A - Zai Lab Ltd (0001704292) (Subject)
Jefferies resumed coverage of Zai Lab with a rating of Buy and set a new price target of $52.00
Scotiabank initiated coverage of Zai Lab with a rating of Sector Outperform and set a new price target of $55.00
BofA Securities downgraded Zai Lab from Buy to Neutral and set a new price target of $36.10 from $29.00 previously
Total revenues grew 9% y-o-y to $110.0 million for the second quarter of 2025; reaffirming full-year 2025 revenue guidance of $560 million to $590 million VYVGART reached record patient utilization in the second quarter; updated national guidelines elevate VYVGART's role as a treatment for both acute and maintenance gMG Operating loss improved by 28% year-over-year to $54.9 million for the second quarter of 2025, and by 37% to $34.2 million on an adjusted basis1; on track to achieve profitability1 in the fourth quarter of 2025 ZL-1310 (DLL3 ADC) data presented at ASCO 2025 showed a 67% ORR across all doses (n=33) and 79% at 1.6mg/kg (n=14) in 2L ES-SCLC, with a differentiate
- Company to host conference call and webcast on August 7, 2025, at 8:00 a.m. ET (8:00 p.m. HKT) Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that it will report its second quarter 2025 financial results and provide recent corporate updates on August 7, 2025, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT). Conference Call and Webcast Information Listeners may access the live webcast by visiting the Company's website at http://ir.zailaboratory.com. Participants must register in advance of the conference call. Details are as follows: Registration link for webcast (preferred):
- Clinically meaningful anti-tumor activity of ZL-1310 observed in heavily pretreated population of patients with small cell lung cancer (SCLC) across dose escalation and expansion cohorts - In second-line (2L) SCLC, objective response rate (ORR) was 67% across all dose levels (n=33) and 79% at 1.6 mg/kg dose (n=14) - Median duration of response has not yet been reached, with 29 of 38 responders remaining on study; 27 of 31 patients with stable disease remaining on study, the majority of whom had tumor regressions - ZL-1310 demonstrated a well-tolerated safety profile at target doses of less than 2.0 mg/kg, with Grade ≥3 treatment-related adverse events (TRAEs) of 6%, and no drug disc
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) announced today that following a distinguished career, Harald Reinhart, M.D., President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases (NSAiID) of Zai Lab, will retire at the end of June, after which he will serve as a senior advisor for the Company. Rafael Amado, M.D., President, Head of Global Oncology Research and Development of Zai Lab, will expand his role and assume responsibility for all of the Company's Global R&D upon Dr. Reinhart's retirement. "Harald has devoted nearly 50 years to treating patients, first as a physician and later discovering and developing innovative therapies to bring to patients in
SHANGHAI and CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced that Michel Vounatsos has been appointed to its Board of Directors, effective January 7, 2023. Mr. Vounatsos brings to the Board extensive global leadership and management experience in the biopharmaceutical industry, including more than 25 years of service at leading companies. His expertise includes significant commercial experience in China and worldwide in the areas of primary care and neuroscience. "We are delighted to welcome Michel Vounatsos to the Zai Lab Board of Directors," said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. "Michel has a wealt
SHANGHAI and CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced the appointment of Rafael G. Amado, M.D. as President, Head of Global Oncology Research and Development, effective December 30, 2022. Dr. Amado brings to Zai Lab deep expertise in the field of oncology and significant global biopharmaceutical R&D leadership. "We are pleased to welcome Rafael to our executive leadership team," said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. "Rafael's experience leading worldwide discovery and clinical development for a number of oncolog
SC 13G - Zai Lab Ltd (0001704292) (Subject)
SC 13G/A - Zai Lab Ltd (0001704292) (Subject)
SC 13G/A - Zai Lab Ltd (0001704292) (Subject)